CA2930912C - Fused 5-membered heteroaryl-imidazole derivatives as modulators of tnf activity - Google Patents

Fused 5-membered heteroaryl-imidazole derivatives as modulators of tnf activity Download PDF

Info

Publication number
CA2930912C
CA2930912C CA2930912A CA2930912A CA2930912C CA 2930912 C CA2930912 C CA 2930912C CA 2930912 A CA2930912 A CA 2930912A CA 2930912 A CA2930912 A CA 2930912A CA 2930912 C CA2930912 C CA 2930912C
Authority
CA
Canada
Prior art keywords
alkyl
methyl
optionally substituted
carboxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2930912A
Other languages
English (en)
French (fr)
Other versions
CA2930912A1 (en
Inventor
Rikki Peter Alexander
Mezher Hussein Ali
Julien Alistair Brown
Victoria Elizabeth JACKSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CA2930912A1 publication Critical patent/CA2930912A1/en
Application granted granted Critical
Publication of CA2930912C publication Critical patent/CA2930912C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2930912A 2013-12-09 2014-12-08 Fused 5-membered heteroaryl-imidazole derivatives as modulators of tnf activity Active CA2930912C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1321731.0 2013-12-09
GBGB1321731.0A GB201321731D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
PCT/EP2014/076842 WO2015086504A1 (en) 2013-12-09 2014-12-08 Imidazothiazole derivatives as modulators of tnf activity

Publications (2)

Publication Number Publication Date
CA2930912A1 CA2930912A1 (en) 2015-06-18
CA2930912C true CA2930912C (en) 2021-10-26

Family

ID=50000414

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2930912A Active CA2930912C (en) 2013-12-09 2014-12-08 Fused 5-membered heteroaryl-imidazole derivatives as modulators of tnf activity

Country Status (11)

Country Link
US (1) US10273247B2 (cg-RX-API-DMAC7.html)
EP (1) EP3080133B1 (cg-RX-API-DMAC7.html)
JP (1) JP6483700B2 (cg-RX-API-DMAC7.html)
CN (1) CN105814065B (cg-RX-API-DMAC7.html)
BR (1) BR112016011522B1 (cg-RX-API-DMAC7.html)
CA (1) CA2930912C (cg-RX-API-DMAC7.html)
ES (1) ES2743190T3 (cg-RX-API-DMAC7.html)
GB (1) GB201321731D0 (cg-RX-API-DMAC7.html)
RU (1) RU2683940C1 (cg-RX-API-DMAC7.html)
TR (1) TR201910983T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015086504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
EP3286195A1 (en) 2015-04-17 2018-02-28 AbbVie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TW201920202A (zh) * 2017-08-17 2019-06-01 瑞士商愛杜西亞製藥有限公司 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
US20240002401A1 (en) * 2020-11-16 2024-01-04 Guangzhou Henovcom Bioscience Co., Ltd. Imidazothiazole compounds, pharmaceutical compositions, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463212A1 (en) * 1990-06-27 1992-01-02 Nikken Chemicals Co., Ltd. Imidazo[2,1-b]thiazole compound anti-ulcer agent containing the same
US5577987A (en) 1994-07-07 1996-11-26 Precise Exercise Equipment Co. Abdominal exerciser device
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
JP2002167389A (ja) * 2000-09-20 2002-06-11 Nikken Chem Co Ltd 新規チアゾールニ環化合物
CA2523336A1 (en) * 2003-04-30 2004-11-11 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
CN1823072A (zh) * 2003-05-15 2006-08-23 艾科尔公司 作为p38抑制剂的咪唑并噻唑和咪唑并噁唑衍生物
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
WO2011132048A1 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
BR112016011522A2 (cg-RX-API-DMAC7.html) 2017-08-08
EP3080133A1 (en) 2016-10-19
US20160376290A1 (en) 2016-12-29
ES2743190T3 (es) 2020-02-18
CN105814065B (zh) 2018-11-23
TR201910983T4 (tr) 2019-08-21
CN105814065A (zh) 2016-07-27
JP6483700B2 (ja) 2019-03-13
GB201321731D0 (en) 2014-01-22
US10273247B2 (en) 2019-04-30
RU2683940C1 (ru) 2019-04-03
WO2015086504A1 (en) 2015-06-18
RU2016127226A (ru) 2018-01-23
EP3080133B1 (en) 2019-07-10
CA2930912A1 (en) 2015-06-18
BR112016011522B1 (pt) 2022-10-25
JP2016539968A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
CA2931019C (en) Imidazopyrimidine derivatives as modulators of tnf activity
CA2930754C (en) Pyrazolopyridine derivatives as modulators of tnf activity
CA2931583C (en) Imidazopyridine derivatives as modulators of tnf activity
CA2930499C (en) Imidazopyridine derivatives as modulators of tnf activity
CA2930866C (en) Imidazotriazine derivatives as modulators of tnf activity
CA2930142C (en) Tetrahydrobenzimidazole derivatives as modulators of tnf activity
CA2930209C (en) Tetrahydroimidazopyridine derivatives as modulators of tnf activity
CA2931586C (en) Imidazopyridine derivatives as modulators of tnf activity
CA2931026C (en) Imidazopyridazine derivatives as modulators of tnf activity
CA2931581C (en) Purine derivatives as modulators of tnf activity
CA2930757C (en) Tetrahydroimidazopyridine derivatives as modulators of tnf activity
CA2931578C (en) Triazolopyridine derivatives as modulators of tnf activity
WO2015086508A1 (en) Benzotriazole derivatives as modulators of tnf activity
EP3080133B1 (en) Imidazothiazole derivatives as modulators of tnf activity
CA2930345A1 (en) Triazolopyridazine derivatives as modulators of tnf activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191120

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240722